PD-L1 expression in recurrent head and neck squamous cell carcinoma

被引：9

作者：

Delafoy, Alice ^{[1
]}

Uguen, Arnaud ^{[2
]}

Lemasson, Gilles ^{[2
]}

Conan-Charlet, Virginie ^{[2
]}

Pradier, Olivier ^{[1
,3
]}

Lucia, Francois ^{[1
,3
]}

Schick, Ulrike ^{[1
,3
]}

机构：

[1] Univ Hosp Morvan, Dept Radiat Oncol, 2 Ave Foch, F-29200 Brest, France

[2] Univ Hosp Morvan, Dept Pathol, 2 Ave Foch, F-29200 Brest, France

[3] Univ Brest, LaTIM, INSERM, UMR 1101,ISBAM,UBO,UBL, Brest, France

来源：

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY | 2022年 / 279卷 / 01期

关键词：

PD-L1; expression; Local recurrences; Radiotherapy; Head and neck cancer; Prognosis; HPV-ASSOCIATED HEAD; PROGRAMMED DEATH-1; COST-EFFECTIVENESS; CLINICAL ACTIVITY; METASTATIC HEAD; OPEN-LABEL; T-CELLS; IMMUNOTHERAPY; NIVOLUMAB; CANCER;

D O I：

10.1007/s00405-021-06777-7

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Purpose To evaluate the Programmed Cell Death Ligand (PD-L1) expression at diagnosis and relapse in patients with head and neck carcinoma (HNSCC) treated with radio(chemo)therapy. Methods PD-L1 immunohistochemistry was performed in tumor cells (TC) and immune cells (IC) in 44 patients and scored as 0 = 0%, 1 = < 5%, 2 = 6-49% or 3 = >= 50% cells. Results PD-L1 expression on TC before RT was scored as 0, 1, 2 and 3 in 28, 4, 8 and 4 patients, respectively. In 10 patients, IC did not show any PD-L1 expression; while in 8, 16, and 10 patients, PD-L1 expression was scored 1, 2 and 3, respectively. At relapse, 7/36 patients had a PD-L1 expression positivation in TC, while the opposite was observed in 6 patients. Overall, survival at 2 years was higher in patients with PD-L1 expression (90% versus 62.5%, p = 0.032). Conclusion PD-L1 expression may vary throughout the course of the disease. A re-evaluation of PD-L1 expression on biopsies at the time of recurrence should be recommended.

引用

页码：343 / 351

页数：9

共 35 条

[1] PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer [J].

Badoual, Cecile ;

Hans, Stephane ;

Merillon, Nathalie ;

Van Ryswick, Cordelia ;

Ravel, Patrice ;

Benhamouda, Nadine ;

Levionnois, Emeline ;

Nizard, Mevyn ;

Si-Mohamed, Ali ;

Besnier, Nicolas ;

Gey, Alain ;

Rotem-Yehudar, Rinat ;

Pere, Helene ;

Tran, Thi ;

Guerin, Coralie L. ;

Chauvat, Anne ;

Dransart, Estelle ;

Alanio, Cecile ;

Albert, Sebastien ;

Barry, Beatrix ;

Sandoval, Federico ;

Quintin-Colonna, Francoise ;

Bruneval, Patrick ;

Fridman, Wolf H. ;

Lemoine, Francois M. ;

Oudard, Stephane ;

Johannes, Ludger ;

Olive, Daniel ;

Brasnu, Daniel ;

Tartour, Eric .

CANCER RESEARCH, 2013, 73 (01) :128-138

[2] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[3] Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers [J].

Carbognin, Luisa ;

Pilotto, Sara ;

Milella, Michele ;

Vaccaro, Vanja ;

Brunelli, Matteo ;

Calio, Anna ;

Cuppone, Federica ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Chilosi, Marco ;

Bronte, Vincenzo ;

Scarpa, Aldo ;

Bria, Emilio ;

Tortora, Giampaolo .

PLOS ONE, 2015, 10 (06)

[4] Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma [J].

Cho, Young-Ah ;

Yoon, Hye-Jung ;

Lee, Jae-Il ;

Hong, Sam-Pyo ;

Hong, Seong-Doo .

ORAL ONCOLOGY, 2011, 47 (12) :1148-1153

[5] Immunotherapy for head and neck cancer: advances and deficiencies [J].

De Costa, Anna-Maria ;

Young, M. Rita I. .

ANTI-CANCER DRUGS, 2011, 22 (07) :674-681

[6] Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J].

Deng, Liufu ;

Liang, Hua ;

Burnette, Byron ;

Beckett, Michael ;

Darga, Thomas ;

Weichselbaum, Ralph R. ;

Fu, Yang-Xin .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :687-695

[7] Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade [J].

Dovedi, Simon J. ;

Adlard, Amy L. ;

Lipowska-Bhalla, Grazyna ;

McKenna, Conor ;

Jones, Sherrie ;

Cheadle, Eleanor J. ;

Stratford, Ian J. ;

Poon, Edmund ;

Morrow, Michelle ;

Stewart, Ross ;

Jones, Hazel ;

Wilkinson, Robert W. ;

Honeychurch, Jamie ;

Illidge, Tim M. .

CANCER RESEARCH, 2014, 74 (19) :5458-5468

[8] Molecular profiling of head and neck squamous cell carcinoma [J].

Feldman, Rebecca ;

Gatalica, Zoran ;

Knezetic, Joseph ;

Reddy, Sandeep ;

Nathan, Cherie-Ann ;

Javadi, Nader ;

Teknos, Theodoros .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 :E1625-E1638

[9] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[10] Immunology and Immunotherapy of Head and Neck Cancer [J].

Ferris, Robert L. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) :3293-+

← 1 2 3 4 →